The Unseen Dilemma: Profit Over Patients in The Pharmaceutical Industry

An in-depth look into how pricing practices and unethical behaviour within the pharmaceutical industry affect access to essential drugs and healthcare sustainability. This article explores the power dynamics, regulations, and significant cases, offering a comprehensive analysis of the issues surrounding the industry.

Oct 8, 2023 - 08:47

0 30

The Unseen Dilemma: Profit Over Patients in The Pharmaceutical Industry

Profound Power and Influence: Inside the Profit-Driven Pharma Industry

The pharmaceutical industry, with its immense power and influence, plays a critical role in providing access to essential medications and ensuring the sustainability of healthcare systems. However, the industry's profit-driven motives and unethical behaviour have often come into conflict with the well-being of patients. This article delves into the pricing practices and questionable conduct within the pharmaceutical sector, shedding light on the profound impact they have on drug accessibility and healthcare sustainability. We aim to provide a thorough analysis of the unseen problem that patients around the world face by looking at significant cases and investigating the industry's influence on regulatory bodies.

The pharmaceutical industry, characterised by a handful of dominant companies, wields immense power and influence over the development, pricing, and availability of drugs. The primary objective of these companies is to maximise profits, often at the expense of patients' well-being.

One infamous case that exemplifies this profit-driven approach is the story of Martin Shkreli, the former CEO of Turing Pharmaceuticals. Shkreli gained notoriety for drastically increasing the price of a life-saving drug, Daraprim, by 5,000%. This sudden price hike limited access to the medication for patients in need, highlighting the industry's greed and lack of consideration for the vulnerable.

Pharmaceutical giants like Novartis, Pfizer, Johnson & Johnson, Roche, and Sanofi dominate the market through acquisitions and mergers. While consolidation may lead to efficiency and innovation, these companies have faced criticism for downplaying clinical trial results and releasing drugs with severe side effects. This disregard for patient safety further underscores the industry's prioritisation of profits over patients.

Unchecked Consequences: Case Studies of Pharmaceutical Companies

Several significant cases expose the unethical practices and consequences of the pharmaceutical industry's profit-driven motivations.

Martin Shkreli and Turing Pharmaceuticals

Martin Shkreli's price hike for Daraprim, an essential drug listed by the World Health Organisation, led to limited accessibility and public outrage. Despite the vital role of this medication in treating parasitic infections, the industry allowed profit considerations to override patient needs.

Depakine and Sanofi's Negligence

The case of Depakine, an epilepsy treatment, exposed the negligence of Sanofi, one of the largest pharmaceutical companies, in notifying health authorities of potential risks. Thousands of children experienced birth defects and mental impairments due to Depakine, a tragedy that could have been avoided with more responsible behaviour from the industry.

Avastin, Lucentis, and Pricing Strategies

The stories of Avastin and Lucentis demonstrated how pharmaceutical companies utilise pricing strategies to maximise profits. Genentech, owned partially by Novartis, marketed Lucentis specifically for age-related macular degeneration (AMD) at a significantly higher price than Avastin, which was accidentally discovered to be effective in treating AMD. This deliberate manipulation of pricing creates financial burdens for patients and healthcare systems, impeding access to affordable and effective treatments.

The Costly Cure: Sovaldi and Gilead Sciences

The introduction of Sovaldi, a drug to cure hepatitis C, raised concerns about access to healthcare due to its exorbitant price. Gilead Sciences priced the treatment at $84,000 for a three-month course, leaving millions of hepatitis C patients unable to afford the cure. While pressure from patients and advocacy groups forced a price reduction, the affordability of life-saving medications still remains a challenge for many.

Escalating Prices: Gene Therapies

Gene therapies hold immense potential for treating diseases like cancer. However, the pricing of these therapies has shown a disturbing trend of escalating costs. Novartis's Kymriah, a therapy for leukaemia, costs an astonishing €320,000 per patient. This pricing strategy further exacerbates the gap between those who can afford life-saving treatments and those who cannot, demonstrating the industry's profit-oriented approach.

Questionable Regulation: The Industry's Influence on Regulatory Bodies

The pharmaceutical industry's influence extends to regulatory bodies, raising concerns about conflicts of interest and compromised regulation.

The industry's financial relationship with regulatory bodies, particularly the U.S. Food and Drug Administration (FDA), creates a potential conflict of interest. Pharmaceutical companies pay significant fees to the FDA for drug evaluation, creating a dependency that compromises regulatory impartiality. This influence undermines the FDA's role in ensuring drug safety and affordability, further endangering patient well-being.

The lack of adequate regulation allows pharmaceutical companies to prioritise profits over patient access to affordable medications. The consequences of this profit-driven mindset are profound and far-reaching. It hinders individuals' access to life-saving drugs and places an immense burden on healthcare systems, making the sustainability of public health systems a growing concern.

The pharmaceutical industry's profit-driven motives and unethical behaviour have a significant impact on patients and healthcare sustainability. The industry's influence over drug development, pricing, and regulatory bodies creates a system that prioritises profits over patient well-being. While regulation and public scrutiny have forced some changes, there is still much work to be done to ensure access to essential medications and the sustainability of healthcare systems. It is crucial for regulators, healthcare providers, and society as a whole to address these issues and demand greater ethical accountability from the pharmaceutical industry.

Okay, Now check this out…

TradeFxP Features

If you choose to be a self-employed retail trader, here are a few things we offer:

The best trading Platform
No Requotes
Lowest Spreads
High level liquidity
Interbank connectivity
Pure STP/DMA/ECN
Free signals
Best support
Crypto Wallet and withdrawals / Deposits (USDT)
Robust CRM
TradeFxP wallet
Once click withdrawal
Multiple payment options
Local offices to walk in
Free VPS
Free Video Chat / Virtual Meetings
And many more…

If you choose to be a part of our managed account programme:

All of the above +
High level risk management
Capital protection
Only 30% of the capital used
Negative balance protection
Our fee is from the profits only
Monthly profit withdrawal
Wallet system – Use it like Phonepe, or google pay
Crypto wallet and withdrawals / Deposits (USDT)
Live monitoring
MyFxbook Live monitoring
Copy Trading
And many more…

Optional: If you do not withdraw your profits for 2 months, our system will use those profits to trade and will keep your 100% capital safe and secure for margin purposes. This is optional, and if you choose not to be a part of it, you can withdraw your profits from the first month itself.

If you choose to be a part of us as an introducing broker (IB) or channel partner,